Horan Christopher sold $80K of ARTV

Horan Christopher (Chief Tech Operations Officer) sold 20,546 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 on 2026-11-17.

Original reporting
SEC EDGAR · Horan Christopher
Published Nov 18, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

Insider selling can influence sentiment, but this disclosure alone does not provide new operational or financial information about Artiva.

02

Market read

Traders may note the modest insider sale as a sentiment datapoint, but it is unlikely to drive a material repricing without accompanying company news.

03

What to watch

No 10b5-1 plan is cited, but the article does not provide context on prior grants, tax events, or whether sales were part of a broader planned schedule.

Relevance 3/10Novelty 3/10Timing: filed 2026-11-18, transaction dated 2026-11-17

Background

The article is an SEC Form 4 insider transaction for Artiva Biotherapeutics, Inc. (ARTV).

Company-level read

Ticker impact

$ARTVNeutralHigh confidence
Context

Artiva Biotherapeutics insider Horan Christopher sold 20,546 shares at $3.9119 on 2026-11-17, totaling about $80.4K, per Form 4.

Expected impact

Likely limited downside pressure or neutral reaction as the market treats it as non-fundamental insider selling.

Evidence & confidence

The filing is an insider transaction disclosure, not an earnings, guidance, deal, or regulatory event; the dollar value is modest and there is no stated company-specific catalyst.

Market effects

Minimal, as this is a single-company insider sale without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or personal liquidity needs and does not necessarily reflect negative views on Artiva’s prospects.

Key entities

  • Artiva Biotherapeutics, Inc.

    US-listed biotech subject of the Form 4 insider sale by its Chief Tech Operations Officer.

  • Horan Christopher

    Chief Tech Operations Officer who sold 20,546 shares on 2026-11-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.